HOUSTON / Jul 20, 2023 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three and six months ended June 30, 2023 on Tuesday, August 8, 2023, after the stock market closes, with the conference call to follow the next morning, on Wednesday, August 9, 2023.
Conference Call | Date: | Wednesday, August 9, 2023 | |
| Time: | 10:30 am Eastern/9:30 am Central | ||
| Dial-In Number: | (866) 952-8559 Primary or | ||
| Conference ID: USPHQ223 | |||
(In order to join this conference call, you will be required to provide the Conference ID listed above) | |||
| To participate, please call in 10 minutes prior to start time. | |||
To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 7, 2023 at U.S. Physical Therapy’s website.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 656 outpatient physical therapy clinics in 40 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 43 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com The information included on that website is not incorporated into this press release.
| Last Trade: | US$73.52 |
| Daily Change: | -0.33 -0.45 |
| Daily Volume: | 111,381 |
| Market Cap: | US$1.120B |
November 05, 2025 August 06, 2025 August 01, 2025 April 30, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
